CBD helped adults with drug-resistant epilepsy regardless of whether they had approved diagnoses

No significant difference in responder rates (greater than 50% seizure reduction) between authorized-indication patients (31.3%) and off-label patients (35.6%, p=0.85). One-year retention rates were also similar (75.0% vs. 74.6%). Among off-label patients, clobazam co-prescription strongly predicted response (71.4% of responders vs. 28.9% of non-responders took clobazam, p=0.002).

Retrospective study at the epilepsy unit of Pitie Salpetriere Hospital in Paris. Included patients initiating pharmaceutical CBD and followed for at least 1 year. Patients divided into authorized (LGS, Dravet, TSC) and off-label groups. Median follow-up: 24 months.

Pharmaceutical CBD is currently approved only for three specific epilepsy syndromes. This real-world data suggests it may benefit a broader population of adults with drug-resistant epilepsy, particularly those already taking clobazam.

As real-world evidence accumulates, the question of whether CBD should be approved for broader epilepsy populations gains traction. This study from a major French epilepsy center adds to evidence that the current approved indications may be too narrow.

Retrospective, single-center design with no randomization or placebo control. Relatively small sample. The strong clobazam association may reflect a pharmacokinetic interaction (CBD inhibits clobazam metabolism) rather than true synergy. No blinding.